Conquering the final frontier in lung transplantation - Mesenchymal stromal cell therapy for chronic lung allograft dysfunction

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1103789

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Lung transplantation remains the only treatment option for an increasing number of Australians with end-stage lung disease, however long-term outcomes are severely compromised by the almost universal development of chronic rejection. Mesenchymal stromal cells (MSCs) hold great promise in treating rejection, and in a world-first we have recently demonstrated that this approach is safe. In another world-first, this randomized, controlled study will determine whether MSC therapy is effective.

Funded Activity Details

Start Date: 01-01-2016

End Date: 01-01-2021

Funding Scheme: Project Grants

Funding Amount: $1,887,790.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Respiratory Diseases

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

bronchiolitis obliterans syndrome | cell therapy | clinical trial | lung transplantation | rejection

Related Links